<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073172</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00018789</org_study_id>
    <secondary_id>NCI-2021-09431</secondary_id>
    <secondary_id>STUDY00018789</secondary_id>
    <nct_id>NCT05073172</nct_id>
  </id_info>
  <brief_title>StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients</brief_title>
  <official_title>A Randomized Intra-Patient Controlled Study of StrataXRT Â® Versus Current Practice to Prevent and Treat Radiation Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the effect of StrataXRT in preventing and treating radiation&#xD;
      dermatitis in breast cancer or head and neck cancer patients. Radiotherapy is often&#xD;
      associated with multiple side effects. These side effects can cause patient injury and make&#xD;
      it difficult to complete treatment. For example, radiation dermatitis or skin damage may&#xD;
      result in severe skin peeling and skin irritation. Depending on the location of radiation,&#xD;
      the skin damage can cause problems and be tough to heal. This trial aims to see whether&#xD;
      StrataXRT may help to prevent dermatitis after radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Compare efficacy of silicone-based film forming topical gel (StrataXRT) versus (vs.)&#xD;
      standard of care skin maintenance.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate overall effectiveness of StrataXRT. II. Evaluate post-radiation therapy (RT)&#xD;
      recovery time for StrataXRT compared to standard of care.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To assess patient reported outcomes. II. Evaluate cost of StrataXRT for management of&#xD;
      radiation dermatitis compared to standard of care skin maintenance.&#xD;
&#xD;
      III. Evaluate the reduction in RT interruption/extension of overall duration of receiving RT&#xD;
      based on the reduced skin toxicity.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients apply StrataXRT topically to the affected area once or twice daily starting&#xD;
      from the first dose of radiation therapy until dermatitis has returned to grade =&lt; 1.&#xD;
&#xD;
      ARM II: Patients receive standard of care including calendula and/or petrolatum-mineral&#xD;
      oil-lanolin-ceresin ointment (Aquaphor) applied 2-6 times daily plus hydrogel or silver&#xD;
      sulfadiazine (Silvadene) or topical corticosteroids applied twice daily starting from the&#xD;
      first dose of radiation therapy until dermatitis has returned to grade =&lt; 1.&#xD;
&#xD;
      After completion of study, patients are followed up at 6 days and 3 weeks post-RT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiation dermatitis</measure>
    <time_frame>Day 0 post-radiation therapy (RT)</time_frame>
    <description>Will be assessed by Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 2+ radiation dermatitis</measure>
    <time_frame>Day 0 post-RT</time_frame>
    <description>Will be assessed by CTCAE version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 2+ radiation dermatitis</measure>
    <time_frame>Day 6 +/- 1 post-RT</time_frame>
    <description>Will be assessed by CTCAE version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Common Terminology Criteria for Adverse Events (CTCAE) scores</measure>
    <time_frame>Up to week 3 post-RT</time_frame>
    <description>Will continue to assess CTCAE score for radiation dermatitis until resolution of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak Common Terminology Criteria for Adverse Events (CTCAE) score</measure>
    <time_frame>Up to week 3 post-RT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-RT recovery time (to grade =&lt; 1 radiation dermatitis</measure>
    <time_frame>Up till entire irradiated treatment site healed (grade =&lt; 1 dermatitis)</time_frame>
    <description>Will be defined by Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Weekly Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) scores</measure>
    <time_frame>Up to week 3 post-RT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average cost of StrataXRT tubes</measure>
    <time_frame>Until healed (grade =&lt; 1 dermatitis), up to 10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of use of skin care products in addition to StrataXRT</measure>
    <time_frame>Until healed (grade =&lt; 1 dermatitis), up to 10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall RT duration</measure>
    <time_frame>Day 0 post-RT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of days missed (attributable to patient or provider concern re: dermatologic toxicity)</measure>
    <time_frame>Day 0 post-RT</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Head and Neck Carcinoma</condition>
  <condition>Radiation-Induced Dermatitis</condition>
  <arm_group>
    <arm_group_label>Arm I (StrataXRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply StrataXRT topically to the affected area once or twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =&lt; 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care including calendula and/or Aquaphor applied 2-6 times daily plus hydrogel or Silvadene or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =&lt; 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calendula Ointment</intervention_name>
    <description>Applied topically</description>
    <arm_group_label>Arm II (standard of care)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment</intervention_name>
    <description>Applied topically</description>
    <arm_group_label>Arm II (standard of care)</arm_group_label>
    <other_name>Aquaphor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Polyethylene Glycol Hydrogel</intervention_name>
    <description>Applied topically</description>
    <arm_group_label>Arm II (standard of care)</arm_group_label>
    <other_name>PEG Hydrogel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silicone-based Film Forming Topical Gel</intervention_name>
    <description>Applied topically</description>
    <arm_group_label>Arm I (StrataXRT)</arm_group_label>
    <other_name>Silicone-based Film-forming Gel Dressing</other_name>
    <other_name>StrataCTX</other_name>
    <other_name>StrataXRT</other_name>
    <other_name>StrataXRT Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silver Sulfadiazine</intervention_name>
    <description>Applied topically</description>
    <arm_group_label>Arm II (standard of care)</arm_group_label>
    <other_name>Flamazine</other_name>
    <other_name>Silvadene</other_name>
    <other_name>Sliverex</other_name>
    <other_name>SSD</other_name>
    <other_name>Sulfadiazine Silver</other_name>
    <other_name>Thermazene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be adult (&gt; age of 18) patients. Both men and women and members of all&#xD;
             races and ethnic groups will be included&#xD;
&#xD;
          -  Histologically confirmed malignancy for which standard curative measures in&#xD;
             conjunction with radiotherapy are indicated to the following sites: whole&#xD;
             breast/chest-wall for post-surgical radiotherapy or bilateral neck (levels one through&#xD;
             six) for head and neck cancer&#xD;
&#xD;
          -  All head and neck cancer patients should have the left and right neck treated to the&#xD;
             same dose when receiving bilateral neck irradiation&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically evident skin involvement of malignancy&#xD;
&#xD;
          -  Thin patients with nodal involvement requiring bolus&#xD;
&#xD;
          -  Patients with significant unshaven facialor chest wall hair compromising film&#xD;
             application&#xD;
&#xD;
          -  Evidence of active cellulitis or wound infection involving anticipated treatment site&#xD;
&#xD;
          -  History of prior radiotherapy to involved site within 5 cm of anticipated treatment&#xD;
             field&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt;= 3&#xD;
&#xD;
          -  Patients receiving concurrent capecitabine&#xD;
&#xD;
          -  Patient with skin grafts over treatment site(s)&#xD;
&#xD;
          -  Presence of psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule. (i.e.&#xD;
             schizophrenia, autism, temporary housing during treatment, scheduling conflict&#xD;
             immediately after treatment. This will need to be assessed prior to consent&#xD;
&#xD;
          -  Actual or perceived inability to reliably apply StrataXRT to the patients treatment&#xD;
             field in the home environment&#xD;
&#xD;
          -  Anticipated or actual use of other non-study topical medications or remedies in the&#xD;
             treatment field&#xD;
&#xD;
          -  Vulnerable populations (pregnant women, decisionally impaired adults, and prisoners)&#xD;
             will be excluded from the study&#xD;
&#xD;
          -  Patients receiving ultra-hypofractionated radiation to the breast&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiri A Cook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kiri A. Cook, MD</last_name>
      <phone>503-494-8756</phone>
      <email>cooki@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Kiri A. Cook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Kiri Cook, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfadiazine</mesh_term>
    <mesh_term>Silver Sulfadiazine</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
    <mesh_term>Mineral Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

